Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2017-02-24

Clinical Trial Update: Efficacy and Safety of Biphasic Insulin Aspart 30 FlexPen™ in Subjects With Type 2 Diabetes [Phase 4]

View source ↗

Summary

A Phase 4 completed trial evaluating the efficacy and safety of Biphasic Insulin Aspart 30 FlexPen in adults with Type 2 diabetes mellitus.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Biphasic Insulin Aspart 30 FlexPen (biphasic insulin aspart 30)

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Diabetes, Diabetes Mellitus, Type 2 | Phase 4 | Status: COMPLETED